Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s

Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s
Qu Biologics soon will begin recruiting participants for a Phase 2 clinical trial to continue investigating the company’s special platform of immunotherapies, collectively called Site Specific Immunomodulators (SSIs), as a potential therapy for Crohn’s disease. Patients’ enrollment will open soon in five clinical trial sites throughout Canada, first in Vancouver and New Westminster, followed by Vernon, British Columbia and Hamilton, Ontario. More information on the trial and enrollment requirements is available here. The investigational QBECO SSI therapy was designed to restore the body’s normal immune function in cancer and immune-related diseases, such as Crohn’s disease. In a previous Phase 1/2, placebo-controlled study (NCT01809275), 68 adult patients with moderate-to-severe Crohn’s disease were randomized to either take QBECO SSI or placebo for eight weeks. Those who responded to treatment continued the therapy — QBECO or placebo — for another eight weeks. Those who failed to respond went on an “open-label” regiment with QBECO treatment for the next eight weeks. The results showed that 50% of the patients achieved clinical remission after being treated for eight weeks with QBECO-SSI, compared to 23% of patients treated with placebo. About 40% of patients who had previously received anti-TNF-alpha therapies were in remission by the end of the 16 weeks of treatment. In th
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *